SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 15351541.
  • 2
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280: 20772082.
  • 3
    Harris ST, Watts N, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282: 13441352.
  • 4
    Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11: 8391.
  • 5
    Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 12411249.
  • 6
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344: 333340.
  • 7
    Boonen S, Laan RF, Barton IP, Watts NB 2005 Effect of osteoporosis treatments on ris of non-vertebral fractures: Review and meta-analysis of intent-to-treat studies. Osteoporos Int 16: 12911298.
  • 8
    Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112: 281289.
  • 9
    Delmas PD, Seeman E 2004 Changes in bone mineral density explain little of the reduction in vertebral or non vertebral fracture risk with antiresorptive therapy. Bone 35: 12221226.
  • 10
    Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27: 687694.
  • 11
    Follet H, Boivin G, Rumelhart C, Meunier PJ 2004 The degree of mineralization is a determinant of bone strength: A study on human calcanei. Bone 34: 783789.
  • 12
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 10511056.
  • 13
    Odvina CV, Zerwekh JE, Rao SD, Maalouf N, Gottschalk FA, Pak CYC 2005 Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 12941301.
  • 14
    Woo SB, Hellstein JW, Kalmar JR 2006 Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753761.
  • 15
    Frost H 1960 Presence of microscopic cracks in vivo in bone. Henry Ford Med Bull 8: 2735.
  • 16
    Schaffler MB 2003 Role of bone turnover in microdamage. Osteoporos Int 14(Suppl 5): S73S80.
  • 17
    Burr DB, Martin RB, Schaffler MB, Radin EL 1985 Bone remodeling in response to in vivo fatigue microdamage. J Biomech 18: 189200.
  • 18
    Mori S, Burr DB 1993 Increased intracortical remodeling following fatigue damage. Bone 14: 103109.
  • 19
    Bentolila V, Boyce TM, Fyhrie DP 1998 Intracortical remodelling in adult rat long bones after fatigue loading. Bone 23: 275281.
  • 20
    Mashiba T, Hirano T, Turner CH, Forwood M, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increases mirodamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15: 613620.
  • 21
    Mashiba T, Turner CH, Hirano T, Forwood M, Johnston CC, Burr DB 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biochemical properties in clinically relevant skeletal sites in beagles. Bone 28: 524531.
  • 22
    Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanashi J, Norimatsu H 2003 Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18: 512520.
  • 23
    Forwood MR, Burr DB, Takano Y, Eastman DF, Smith PN, Schwardt JD 1995 Risedronate treatment does not increase microdamage in the canine femoral neck. Bone 16: 643650.
  • 24
    Allen MR, Iwata K, Phipps R, Burr DB 2006 Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39: 872879.
  • 25
    Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Roriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 11891199.
  • 26
    Recker R, Ensrud K, Diem S, Cheng E, Bare S, Masarachia P, Roschger P, Fratzl P, Klaushofer K, Lombardi A, Kimmel D 2004 Normal bone histomorphometry and 3D microarchitecture after 10 years of alendronate treatment of postmenopausal women. J Bone Miner Res 19: S1; S45.
  • 27
    Ste-Marie LG, Sod E, Johnson T, Chines A 2004 Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75: 469476.
  • 28
    Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Painner A, Petto H, Westmore M, Michalsky D, Sato M, Dobnig H 2007 Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone (in press).
  • 29
    Chavassieux P, Arlot M, Meunier PJ 2001 Clinical use of bone biopsy. MarcusR, FeldmanD, KelseyJ (eds.) Osteoporosis, 2nd ed., vol 2. Academic Press, San Diego, CA, USA, 501509.
  • 30
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2: 595610.
  • 31
    Burr DB, Stafford T 1990 Validity of the bulk-staining technique to separate artifactual from in vivo bone microdamage. Clin Orthop 260: 305308.
  • 32
    Burr DB, Hooser M 1995 Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. Bone 17: 431433.
  • 33
    Lee TC, Arthur TL, Gibson LJ, Hayes WC 2000 Sequential labeling of microdamage in bone using chelating agents. J Orthop Res 18: 322325.
  • 34
    Zarrinkalam KH, Kuliwaba JS, Martin RB, Wallwork MAB, Fazzalari NL 2005 New insights into the propagation of fatigue damage in cortical bone using confocal microscopy and chelating fluorochromes. Eur J Morphol 42: 8190.
  • 35
    Mohsin S, O'Brien FJ, Lee TC 2006 Osteonal crack barriers in ovine compact bone. J Anat 208: 8189.
  • 36
    Schaffler MB, Choi K, Milgrom C 1995 Aging and matrix microdamage accumulation in human compact bone. Bone 17: 521525.
  • 37
    Norman TL, Wang Z 1997 Microdamage of human cortical bone: Incidence and morphology in long bones. Bone 20: 375379.
  • 38
    Mori S, Harruff R, Ambrosius W, Burr DB 1997 Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone 21: 521526.
  • 39
    Fazzalari NL, Forwood MR, Smith K, Manthey BA, Herreen P 1998 Assessment of cancellous bone quality in severe osteoarthritis: Bone mineral density, mechanics, and microdamage. Bone 22: 381388.
  • 40
    Wenzel T, Schaffler MB, Fyhrie D 1996 In vivo trabecular microcracks in human vertebral bone. Bone 19: 8995.
  • 41
    Arlot ME, Delmas PD, Chappard D, Meunier PJ 1990 Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: Comparison with normal postmenopausal osteoporosis. Osteoporos Int 1: 4149.
  • 42
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79: 16931700.
  • 43
    Black DM, Schwartz A, Ensrud K, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial long-Term Extension (FLEX): A randomized trial. JAMA 296: 29272938.
  • 44
    Watts NB 2004 Effect of risedronate treatment discontinuation on bone turnover and BMD. Calcif Tissue Int 74(Suppl 1): S79.
  • 45
    Reid IR, Brown JP, Burkhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, DiMicco R, Genazzani R, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Verbruggen L, Meunier PJ 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346: 653661.
  • 46
    Nyman JS, Yeh OC, Hazelwood SJ, Martin RB 2004 A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage. Bone 35: 296305.
  • 47
    Allen MR, Burr DB 2006 Microdamage is self limited in beagles treated for three years with clinical doses of alendronate. J Bone Miner Res 21: S1; S70.